Resolution of Refractory Multifocal Atrial Tachycardia in C ostello Syndrome Using Trametinib: A Case Supporting MEK Inhibitors as Targeted, Specific Antiarrhythmic
American Journal of Medical Genetics Part A · 2026-09 · 200 (9) · 2151-2156
DOI: 10.1002/ajmg.a.70180 ↗Kurz gefasst
Fallbericht in der Zeitschrift American Journal of Medical Genetics Part A, online erschienen am 27.04.2026. Verfasst von Vanina Taliercio und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Medical Genetics, University of Utah, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Pyridones, Pyrimidinones, Costello Syndrome, Anti-Arrhythmia Agents. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Arrhythmias affect approximately half of patients with Costello syndrome (CS, OMIM # 218040), with non‐reentrant atrial tachycardia being the most common. This case describes an infant with Costello syndrome carrying the pathogenic HRAS c.34G>A (p.G12S) variant who developed early‐onset, drug‐refractory multifocal atrial tachycardia (MAT). Despite multiple antiarrhythmic therapies, rhythm control remained inadequate until trametinib was initiated, resulting in rapid resolution of MAT and allowing stepwise discontinuation of adjunct antiarrhythmics. Although MAT did not recur after the MEK inhibitor was stopped, the patient subsequently developed hypertrophic cardiomyopathy only after trametinib was discontinued, suggesting a potential disease‐modifying cardioprotective effect during active treatment. This case supports MEK inhibition as a targeted antiarrhythmic strategy in Costello syndrome, with benefits that may extend beyond acute rhythm stabilization to include prevention of cardiac hypertrophy. While spontaneous resolution of MAT can occur in Costello syndrome, the rapid and sustained response in this patient strengthens the hypothesis that trametinib exerts a direct antiarrhythmic effect.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Division of Medical Genetics, University of Utah, Salt Lake City, Utah, USA.
- Department of Pediatrics, Division of General Pediatrics, University of Utah, Salt Lake City, Utah, USA.
- Department of Pediatrics, Division of Cardiology, University of Utah, Salt Lake City, Utah, USA.
ORCID-Profile: Vanina Taliercio, Josue Flores Daboub
Zitieren
APA
Taliercio, V., Wilcox, A., Cole, S., Daboub, J. F., Morales Moreno, J. E., Andrews, K. G., Asaki, S. Y., Pilcher, T. A., Tristani-Firouzi, M., Niu, M. C., Viskochil, D., & Hammond, B. (2026). Resolution of Refractory Multifocal Atrial Tachycardia in C ostello Syndrome Using Trametinib: A Case Supporting MEK Inhibitors as Targeted, Specific Antiarrhythmic. American Journal of Medical Genetics Part A, 200(9), 2151-2156. https://doi.org/10.1002/ajmg.a.70180
Vancouver
Taliercio V, Wilcox A, Cole S, Daboub JF, Morales Moreno JE, Andrews KG, et al. Resolution of Refractory Multifocal Atrial Tachycardia in C ostello Syndrome Using Trametinib: A Case Supporting MEK Inhibitors as Targeted, Specific Antiarrhythmic. American Journal of Medical Genetics Part A. 2026;200(9):2151-2156. doi:10.1002/ajmg.a.70180
BibTeX
@article{Taliercio2026,
author = {Taliercio, Vanina and Wilcox, Annabelle and Cole, Stacey and Daboub, Josue Flores and Morales Moreno, José E and Andrews, Kasey G and Asaki, S Yukiko and Pilcher, Thomas A and Tristani-Firouzi, Martin and Niu, Mary C and Viskochil, David and Hammond, Benjamin},
title = {Resolution of Refractory Multifocal Atrial Tachycardia in C ostello Syndrome Using Trametinib: A Case Supporting MEK Inhibitors as Targeted, Specific Antiarrhythmic},
journal = {American Journal of Medical Genetics Part A},
year = {2026},
volume = {200},
number = {9},
pages = {2151--2156},
doi = {10.1002/ajmg.a.70180}
}
EUVIMED